Clinical Trial: Identification and Description of Patients With High-risk Non Metastatic RCC

U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07753343) titled 'Identification and Description of Patients With High-risk Non Metastatic RCC' on July 20.

Brief Summary: Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decision...